Leaflet KINPARLEV 3mg/24 h transdermal patch

Indicated for: Parkinson's disease

Route of administration: transdermal

Substance: rotigotine (antiparkinsonian agent)

ATC: N04BC09 (Nervous system | Dopaminergic agents | Dopamine agonists)

Precautions:
Driving impairment
Driving impairment

This medicine may affect your ability to drive or use machines.

Dizziness / vertigo
Dizziness / vertigo

This medicine may cause dizziness or vertigo.

Hypotension / fall risk
Hypotension / fall risk

May lower blood pressure and increase the risk of falls.

Drowsiness / sedation
Drowsiness / sedation

This medicine may cause drowsiness or reduced alertness.


Rotigotine is a medication used to treat Parkinson's disease and restless legs syndrome. This medicine helps relieve motor symptoms such as tremor, stiffness, and movement difficulties by stimulating dopamine receptors in the brain. Rotigotine contributes to improving the quality of life for patients with these neurological conditions.

Rotigotine is usually administered as a transdermal patch, applied to the skin once a day. The dose is adjusted by the doctor based on the patient's response and the severity of symptoms. It is important to follow the application instructions and not to stop the treatment without your doctor's approval.

Side effects of rotigotine may include skin reactions, nausea, dizziness, drowsiness, or insomnia. In rare cases, more serious reactions may occur, such as behavioral disorders or hallucinations. If you notice any unusual symptoms, contact your doctor immediately.

Rotigotine is a modern medicine that provides an effective option for controlling the symptoms of Parkinson's disease and restless legs syndrome. Regular monitoring and communication with your doctor are essential for the safety and effectiveness of the treatment. Inform your doctor about any other medications or supplements you are taking.

General data about KINPARLEV 3mg/24 h

  • Substance: rotigotine
  • Product code: W71939001
  • Concentration: 3mg / 24h
  • Pharmaceutical form: transdermal patch
  • Product type: Generic medicine
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: ORION CORPORATION ORION PHARMA - FINLANDA
  • Holder: ORION CORPORATION - FINLANDA
  • Number: 16623/2026/01
  • Shelf life: 2 years

Concentrations available for rotigotine

  • 1mg/24h
  • 2mg/24h
  • 3mg/24h
  • 4mg/24h
  • 6mg/24h
  • 8mg/24h